Patents by Inventor Gunnar J. Hanson

Gunnar J. Hanson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOUNDS FOR TREATMENT OF LYMPHOCYTE-RELATED DISEASES AND CONDITIONS
    Publication number: 20180161359
    Abstract: Methods for treatment of lymphocyte-related diseases and conditions, such as cancer and automimmune diseases, are provided. The methods comprise administration of an effective amount of an oligomer to a patient in need thereof, wherein the oligomer comprises, inter alia, at least one intersubunit linkage having the following structure: wherein R1, L1, X, Y and Z are as defined herein.
    Type: Application
    Filed: June 3, 2016
    Publication date: June 14, 2018
    Inventors: Dan V. Mourich, Gunnar J. Hanson, Frederick Joseph Schnell, Johannes Christian Dworzak
  • Boronic acid conjugates of oligonucleotide analogues
    Patent number: 9920085
    Abstract: Oligonucleotide analogs comprising boronic acid and/or boronic ester moieties are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: March 20, 2018
    Assignee: SAREPTA THERAPEUTICS, INC.
    Inventor: Gunnar J. Hanson
  • Peptide oligonucleotide conjugates
    Patent number: 9862946
    Abstract: Oligonucleotide analogs conjugated to carrier peptides are provided. The disclosed compounds are useful for the treatment of various diseases, for example diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: January 9, 2018
    Assignee: SAREPTA THERAPEUTICS, INC.
    Inventor: Gunnar J. Hanson
  • Functionally-modified oligonucleotides and subunits thereof
    Patent number: 9790499
    Abstract: Functionally-modified oligonucleotide analogs comprising modified intersubunit linkages and/or modified 3? and/or 5?-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.
    Type: Grant
    Filed: January 26, 2016
    Date of Patent: October 17, 2017
    Assignee: SAREPTA THERAPEUTICS, INC.
    Inventors: Gunnar J. Hanson, Dwight D. Weller, Bao Zhong Cai, Ming Zhou
  • OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
    Publication number: 20170198287
    Abstract: Oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3? and/or 5?-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.
    Type: Application
    Filed: August 25, 2016
    Publication date: July 13, 2017
    Inventors: Gunnar J. Hanson, Alexander Charles Rudolph, Bao Zhong Cai, Ming Zhou, Dwight D. Weller
  • FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF
    Publication number: 20160376587
    Abstract: Functionally-modified oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3? and/or 5?-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.
    Type: Application
    Filed: January 26, 2016
    Publication date: December 29, 2016
    Inventors: Gunnar J. Hanson, Dwight D. Weller, Bao Zhong Cai, Ming Zhou
  • Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
    Patent number: 9469664
    Abstract: Oligonucleotide analogs comprising modified intersubunit linkages and/or modified 3? and/or 5?-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: October 18, 2016
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Gunnar J. Hanson, Alexander Charles Rudolph, Bao Zhong Cai, Ming Zhou, Dwight D. Weller
  • PEPTIDE OLIGONUCLEOTIDE CONJUGATES
    Publication number: 20160237426
    Abstract: Oligonucleotide analogues conjugated to carrier peptides are provided. The disclosed compounds are useful for the treatment of various diseases, for example diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.
    Type: Application
    Filed: September 11, 2015
    Publication date: August 18, 2016
    Inventor: Gunnar J. Hanson
  • Functionally-modified oligonucleotides and subunits thereof
    Patent number: 9278987
    Abstract: Functionally-modified oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3? and/or 5?-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.
    Type: Grant
    Filed: November 15, 2012
    Date of Patent: March 8, 2016
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Gunnar J. Hanson, Dwight D. Weller, Bao Zhong Cai, Ming Zhou
  • Antisense modulation of interleukins 17 and 23 signaling
    Patent number: 9238042
    Abstract: Provided are antisense oligonucleotides and other agents that target and modulate IL-17 and/or IL-23 signaling activity in a cell, compositions that comprise the same, and methods of use thereof. Also provided are animal models for identifying agents that modulate 17 and/or IL-23 signaling activity.
    Type: Grant
    Filed: May 13, 2011
    Date of Patent: January 19, 2016
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Frederick J. Schnell, Patrick L. Iversen, Dan V. Mourich, Gunnar J. Hanson
  • Peptide oligonucleotide conjugates
    Patent number: 9161948
    Abstract: Oligonucleotide analogues conjugated to carrier peptides are provided. The disclosed compounds are useful for the treatment of various diseases, for example diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.
    Type: Grant
    Filed: November 17, 2011
    Date of Patent: October 20, 2015
    Assignee: Sarepta Therapeutics, Inc.
    Inventor: Gunnar J. Hanson
  • COMPOUND AND METHOD FOR TREATING MYOTONIC DYSTROPHY
    Publication number: 20150141321
    Abstract: Provided are 9-base morpholino antisense compounds targeted to polyCUG repeats in the 3?UTR region of dystrophia myotonica protein kinase (DMPK) mRNA, and related methods for treating myotonic dystrophy DM1.
    Type: Application
    Filed: August 20, 2014
    Publication date: May 21, 2015
    Inventors: Ryszard Kole, Gunnar J. Hanson
  • BORONIC ACID CONJUGATES OF OLIGONUCLEOTIDE ANALOGUES
    Publication number: 20150080340
    Abstract: Oligonucleotide analogues comprising boronic acid and/or boronic ester moieties are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.
    Type: Application
    Filed: March 7, 2013
    Publication date: March 19, 2015
    Inventor: Gunnar J. Hanson
  • OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
    Publication number: 20150073140
    Abstract: Oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3? and/or 5?-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.
    Type: Application
    Filed: June 6, 2014
    Publication date: March 12, 2015
    Applicant: Sarepta Therapeutics, Inc.
    Inventors: Gunnar J. Hanson, Alexander Charles Rudolph, Bao Zhong Cai, Ming Zhou, Dwight D. Weller
  • FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF
    Publication number: 20140330006
    Abstract: Functionally-modified oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3? and/or 5?-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.
    Type: Application
    Filed: November 15, 2012
    Publication date: November 6, 2014
    Applicant: Sarepta Therapeutics, Inc.
    Inventors: Gunnar J. Hanson, Dwight D. Weller, Bao Zhong Cai, Ming Zhou
  • OLIGONUCLEOTIDES FOR TREATING EXPANDED REPEAT DISEASES
    Publication number: 20140303238
    Abstract: The invention provides for a method for selectively reducing the expression of a mutant mRNA and/or protein having an expanded nucleotide repeat relative to a wild-type mRNA, comprising contacting a cell with an antisense oligonucleotide of sufficient length and complementarity to the expanded nucleotide repeat. More particularly it relates to selectively reducing the expression of mutant Huntington protein associated with Huntington's disease. The antisense oligonucleotide comprising either a nucleotide or a repeated three nucleotide sequence as defined in the claims.
    Type: Application
    Filed: November 30, 2012
    Publication date: October 9, 2014
    Applicant: SAREPTA THERAPEUTICS, INC.
    Inventors: Peter Linsley, Brian James Leppert, Gunnar J. Hanson
  • Compound and method for treating myotonic dystrophy
    Patent number: 8835402
    Abstract: Provided are 9-base morpholino antisense compounds targeted to polyCUG repeats in the 3?UTR region of dystrophia myotonica protein kinase (DMPK) mRNA, and related methods for treating myotonic dystrophy DM1.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: September 16, 2014
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Ryszard Kole, Gunnar J. Hanson
  • Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
    Patent number: 8779128
    Abstract: Oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3? and/or 5?-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.
    Type: Grant
    Filed: May 27, 2011
    Date of Patent: July 15, 2014
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Gunnar J. Hanson, Charles Rudolph, Bao Zhong Cai, Ming Zhou, Dwight D. Weller
  • COMPOUND AND METHOD FOR TREATING MYOTONIC DYSTROPHY
    Publication number: 20140107013
    Abstract: Provided are 9-base morpholino antisense compounds targeted to polyCUG repeats in the 3?UTR region of dystrophia myotonica protein kinase (DMPK) mRNA, and related methods for treating myotonic dystrophy DM1.
    Type: Application
    Filed: September 26, 2013
    Publication date: April 17, 2014
    Applicant: Sarepta Therapeutics, Inc.
    Inventors: Ryszard Kole, Gunnar J. Hanson
  • Small molecule apoptosis promoters
    Patent number: 8586542
    Abstract: The invention provides small molecule mimics of the Smac peptide that are dimer- or dimer-like compounds having two amide-containing domains connected by a linker. These compounds are useful to promote apoptosis. The invention includes pharmaceutical compositions comprising such compounds and methods to use them to treat conditions including cancer and autoimmune disorders.
    Type: Grant
    Filed: June 28, 2012
    Date of Patent: November 19, 2013
    Assignee: Joyant Pharmaceuticals, Inc.
    Inventors: Gunnar J. Hanson, David Thomas, Nizal Chandrakumar, Susan Harran